News
Highly promising data presented
Klas Palin
2026-03-20
10:23 CET
Intervacc has reported new data for its Streptococcus suis vaccine candidate, which we view as highly encouraging and supportive of the underlying commercial opportunity. The company now intends to advance the programme into GMP manufacturing and pivotal clinical studies, representing the next key development milestone. However, at this stage, we leave our fair value unchanged.
What’s new? Late yesterday (19 March), the company reported positive preclinical data for its piglet vaccine candidate targeting Streptococcus suis. The data demonstrated a favourable safety profile and statistically significant protection versus control following challenge with a high dose of a virulent serotype 9 strain. In prior studies, the vaccine has also shown statistically significant protection in piglets against a virulent serotype 2 strain. The company now intends to advance the vaccine into GMP manufacturing and pivotal clinical studies.
What does this mean? The additional serotype 9 data further supports the potential for broader cross-serotype efficacy, which we view as a key consideration for commercial scalability. We note that Streptococcus suis is a leading cause of mortality in piglets and a significant driver of economic losses across the global pork industry, underpinning a clear unmet need, particularly given the absence of commercially available vaccines against these infections.
What do we do? Although still at an early stage of development, the use of challenge studies in the target population provides a degree of de-risking for the programme. Overall, we view this data as highly encouraging and supportive of the commercial opportunity for the vaccine candidate. A vaccine targeting the most prevalent serotypes could represent a larger market opportunity than Strangvac, in our view. We await further clarity on the next development steps to better assess the path towards potential registration. Pending this, we have not yet included the programme into our valuation.